Cost savings through molecular diagnosis for hereditary hemorrhagic telangiectasia

Genetics in Medicine

Volumn 14, Issue 6, 2012, Pages 604-610

  Bernhardt, Barbara A ^a,b   Zayac, Cara ^a,b   Trerotola, Scott O ^a   Asch, David A ^a,b,c   Pyeritz, Reed E ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

cost effectiveness; economic analysis; genetic screening; genetic testing; hereditary hemorrhagic telangiectasia

Indexed keywords

ARTICLE; COST CONTROL; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; HEALTH CARE COST; HEALTH INSURANCE; MOLECULAR DIAGNOSIS; PATIENT ASSESSMENT; REIMBURSEMENT; RENDU OSLER WEBER DISEASE;

ADULT; CHILD, PRESCHOOL; COHORT STUDIES; COST SAVINGS; DATA COLLECTION; FEMALE; GENETIC TESTING; HUMANS; MALE; MUTATION; PEDIGREE; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; YOUNG ADULT;

EID: 84861908400     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2011.56     Document Type: Article

References (34)

1. McDonald J, Bayrak-Toydemir P, Pyeritz RE. Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. Genet Med 2011;13:607-616.
2. Guttmacher A, Marchuck D, Trerotola S, Pyeritz RE. Hereditary hemorrhagic telangiectasia. In: Rimoin DL, Pyeritz RE, Korf BR (eds). Principles and Practice of Medical Genetics (6th edn). Elsevier: Philadelphia, PA: 2012, in press.
3. Faughnan ME, Palda VA, Garcia-Tsao G, et al.; HHT Foundation International - Guidelines Working Group. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011;48:73-87.
4. Trerotola SO, Pyeritz RE. PAVM embolization: an update. AJR Am J Roentgenol 2010;195:837-845.
5. Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000;91:66-67. (Pubitemid 30127562)
6. McDonald J, Damjanovich K, Millson A, et al. Molecular diagnosis in hereditary hemorrhagic telangiectasia: findings in a series tested simultaneously by sequencing and deletion/duplication analysis. Clin Genet 2011;79:335-344.
7. Richards-Yutz J, Grant K, Chao EC, Walther SE, Ganguly A. Update on molecular diagnosis of hereditary hemorrhagic telangiectasia. Hum Genet 2010;128:61-77.
8. Prigoda NL, Savas S, Abdalla SA, et al. Hereditary haemorrhagic telangiectasia: mutation detection, test sensitivity and novel mutations. J Med Genet 2006;43:722-728. (Pubitemid 44483914)
9. Bernhardt BA, Zayac C, Pyeritz RE. Why is genetic screening for autosomal dominant disorders underused in families? The case of hereditary hemorrhagic telangiectasia. Genet Med 2011;13:812-820.
10. Messner DA, Pyeritz RE, Bernhardt BA. Comment on the impact of gene patents and licensing practices on access to genetic testing: lessons from hereditary hemorrhagic telangiectasia. Genet Med 2010;12:746-748.
11. Gallione CJ, Richards JA, Letteboer TG, et al. SMAD4 mutations found in unselected HHT patients. J Med Genet 2006;43:793-797. (Pubitemid 44654737)
12. Cohen JH, Faughnan ME, Letarte M, Vandezande K, Kennedy SJ, Krahn MD. Cost comparison of genetic and clinical screening in families with hereditary hemorrhagic telangiectasia. Am J Med Genet A 2005;137:153-160. (Pubitemid 41262682)
13. Cebul RD, Rebitzer JB, Taylor LJ, Votruba ME. Organizational fragmentation and care quality in the U.S healthcare system. J Econ Perspect 2008;22: 93-113.
14. Nawaz A, Litt HI, Stavropoulos SW, et al. Digital subtraction pulmonary arteriography versus multidetector CT in the detection of pulmonary arteriovenous malformations. J Vasc Interv Radiol 2008;19:1582-1588.
15. van Gent MW, Post MC, Luermans JG, et al. Screening for pulmonary arteriovenous malformations using transthoracic contrast echocardiography: a prospective study. Eur Respir J 2009;33:85-91.
16. Jackson L, Pyeritz RE. Molecular technologies open new clinical genetic vistas. Sci Transl Med 2011;3:65ps2.
17. Haddow JE, Palomaki GE. ACCE: a model process for evaluating data on emerging genetic tests. In: Koury M, Little J, Burke W (eds). Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. Oxford University Press: Oxford, UK, 2003:217-233.
18. Rogowski W. Current impact of gene technology on healthcare. A map of economic assessments. Health Policy 2007;80:340-357. (Pubitemid 44914099)
19. Grosse SD, Wordsworth S, Payne K. Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med 2008;10:648-654.
20. Phillips KA, Veenstra DL, Ramsey SD, Van Bebber SL, Sakowski J. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care 2004;10(7 Pt 1):425-432. (Pubitemid 38970239)
21. Kohane IS, Masys DR, Altman RB. The incidentalome: a threat to genomic medicine. JAMA 2006;296:212-215. (Pubitemid 44050375)
22. Pyeritz RE. The coming explosion in genetic testing-is there a duty to recontact? N Engl J Med 2011;365:1367-1369.
23. Carlson JJ, Henrikson NB, Veenstra DL, Ramsey SD. Economic analyses of human genetics services: a systematic review. Genet Med 2005;7:519-523. (Pubitemid 41566478)
24. Regier DA, Friedman JM, Marra CA. Value for money? Array genomic hybridization for diagnostic testing for genetic causes of intellectual disability. Am J Hum Genet 2010;86:765-772.
25. Perez MV, Kumarasamy NA, Owens DK, Wang PJ, Hlatky MA. Cost-effectiveness of genetic testing in family members of patients with long-QT syndrome. Circ Cardiovasc Qual Outcomes 2011;4:76-84.
26. Ramsey SD, Burke W, Pinsky L, Clarke L, Newcomb P, Khoury MJ. Family history assessment to detect increased risk for colorectal cancer: conceptual considerations and a preliminary economic analysis. Cancer Epidemiol Biomarkers Prev 2005;14(11 Pt 1):2494-2500. (Pubitemid 41754506)
27. Brown ML, Kessler LG. Use of gene tests to detect hereditary predisposition to cancer: what do we know about cost effectiveness? Int J Cancer 1996;69:55-57. (Pubitemid 26083273)
28. Ramsey SD, Burke W, Clarke L. An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. Genet Med 2003;5:353-363. (Pubitemid 37264984)
29. Breheny N, Geelhoed E, Goldblatt J, Ee H, O'Leary P. Economic evaluation of the familial cancer programme in Western Australia: predictive genetic testing for familial adenomatous polyposis and hereditary non-polyposis colorectal carcinoma. Community Genet 2006;9:98-106.
30. Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010;12:93-104.
31. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2011;155:69-79.
32. Higashi MK, Veenstra DL. Managed care in the genomics era: assessing the cost effectiveness of genetic tests. Am J Manag Care 2003;9:493-500. (Pubitemid 36949536)
33. Rogowski WH, Hartz SC, John JH. Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicine. BMC Health Serv Res 2008;8:194.
34. Pollak JS, Saluja S, Thabet A, Henderson KJ, Denbow N, White RI Jr. Clinical and anatomic outcomes after embolotherapy of pulmonary arteriovenous malformations. J Vasc Interv Radiol 2006;17:35-44; quiz, 45.